A5018075974- Mesenchymal stem cell research
- Tissue Engineering and Regenerative Medicine
- Developmental Biology and Gene Regulation
- Hippo pathway signaling and YAP/TAZ
- RNA Interference and Gene Delivery
- MicroRNA in disease regulation
- Electrospun Nanofibers in Biomedical Applications
- Wnt/β-catenin signaling in development and cancer
- Neonatal Respiratory Health Research
- Burn Injury Management and Outcomes
- Hematopoietic Stem Cell Transplantation
- Medicinal Plants and Neuroprotection
- Retinal Development and Disorders
- Cell Adhesion Molecules Research
- Mosquito-borne diseases and control
- CAR-T cell therapy research
- Neurobiology and Insect Physiology Research
- Genetics, Aging, and Longevity in Model Organisms
- Wound Healing and Treatments
- Molecular Biology Techniques and Applications
- Pesticide Exposure and Toxicity
- Genetic Syndromes and Imprinting
- Pluripotent Stem Cells Research
- Animal Genetics and Reproduction
- Epigenetics and DNA Methylation
Emergent BioSolutions (Canada)
2016-2024
Simon Fraser University
2008-2024
Defence Research and Development Canada
2014-2016
Mesenchymal stromal cells (MSCs) offer great potential for diverse clinical applications. However, conventional systemic infusion of MSCs limits their therapeutic benefit, since intravenously (IV) infused become entrapped in the lungs where dwell time is short.To explore possible alternatives to IV infusion, we used vivo optical imaging track bio-distribution and survival 1 million bioluminescent administered IV, intraperitoneally (IP), subcutaneously (SC) intramuscularly (IM) healthy...
Abstract In preclinical studies, mesenchymal stromal cells (MSCs) exhibit robust potential for numerous applications. To capitalize on these benefits, cell manufacturing and delivery protocols have been scaled up to facilitate clinical trials without adequately addressing the impact of processes utility nor inevitable regulatory requirements consistency. Growing evidence indicates that culture-aged MSCs, expanded limits replicative exhaustion generate human doses, are not equivalent early...
: Mesenchymal stromal cells (MSCs) are being exploited as gene delivery vectors for various disease and injury therapies. We provide proof-of-concept that engineered MSCs can a useful, effective platform protection against infectious disease. Venezuelan equine encephalitis virus (VEEV) is mosquito-borne pathogen affecting humans equines be used in bio-warfare. No licensed vaccine or antiviral agent currently exists to combat VEEV infection humans. Direct antibody administration (passive...
Development of standardized metrics to support manufacturing and regulatory approval mesenchymal stromal cell (MSC) products is confounded by heterogeneity MSC populations. Many reports describe fundamental differences between MSCs from various tissues compare unstimulated activated counterparts. However, molecular information comparing biological profiles across different origins donors limited. To better understand common source-specific mechanisms action, we compared the responses 3 donor...
Abstract Drosophila nemo (nmo) is the founding member of Nemo-like kinase (Nlk) family serine–threonine kinases. Previous work has characterized nmo's role in planar cell polarity during ommatidial patterning. Here we examine an earlier for nmo eye formation through interactions with retinal determination gene network (RDGN). dynamically expressed second and third instar imaginal discs, suggesting additional roles patterning eyes, ocelli, antennae. We utilized genetic approaches to...
Abstract Background Mesenchymal stromal cells (MSCs) are rapidly advancing as commercial therapeutics. However, there still no adequate tools to validate the identity of MSCs and support standardization MSC-based products. Currently accepted metrics include cell surface marker profiling tri-lineage differentiation assays, neither which is definitive. Transcript represents a cost- time-effective approach amenable MSC manufacturing processes. Two independent labs recently reported...
Human butyrylcholinesterase (BChE) is a well-characterized bioscavenger with significant potential as prophylactic or post-exposure treatment for organophosphate poisoning. Despite substantial efforts, BChE has proven technically challenging to produce in recombinant systems. Recombinant tends be insufficiently incorrectly glycosylated, and consequently exhibits truncated half-life, compromised activity, immunogenic. Thus, expired human plasma remains the only reliable source of benchmark...